Ness N, Diaz-Clavero S, Hoekstra M, Brancaccio M
EMBO J. 2024; 44(2):356-381.
PMID: 39623138
PMC: 11731042.
DOI: 10.1038/s44318-024-00324-w.
Harsing Jr L, Timar J, Miklya I
Int J Mol Sci. 2023; 24(17).
PMID: 37686140
PMC: 10487936.
DOI: 10.3390/ijms241713334.
Varnas K, Nag S, Halldin C, Farde L
ACS Chem Neurosci. 2023; 14(17):3206-3211.
PMID: 37587571
PMC: 10485887.
DOI: 10.1021/acschemneuro.3c00332.
Ernyey A, Kassai F, Kozma K, Plangar I, Somfai Z, Miklya I
Geroscience. 2023; 46(1):417-429.
PMID: 37306892
PMC: 10828437.
DOI: 10.1007/s11357-023-00821-6.
Naoi M, Maruyama W, Shamoto-Nagai M
Int J Mol Sci. 2022; 23(19).
PMID: 36232361
PMC: 9570229.
DOI: 10.3390/ijms231911059.
The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.
Goldstein D
Int J Mol Sci. 2021; 22(11).
PMID: 34206133
PMC: 8199574.
DOI: 10.3390/ijms22115999.
Monoamine Oxidase Inhibitors: A Review of Their Anti-Inflammatory Therapeutic Potential and Mechanisms of Action.
Ostadkarampour M, Putnins E
Front Pharmacol. 2021; 12:676239.
PMID: 33995107
PMC: 8120032.
DOI: 10.3389/fphar.2021.676239.
SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer's Disease.
Unzeta M, Hernandez-Guillamon M, Sun P, Sole M
Int J Mol Sci. 2021; 22(7).
PMID: 33805974
PMC: 8036996.
DOI: 10.3390/ijms22073365.
Chronic Oral Selegiline Treatment Mitigates Age-Related Hearing Loss in BALB/c Mice.
Szepesy J, Humli V, Farkas J, Miklya I, Timar J, Tabi T
Int J Mol Sci. 2021; 22(6).
PMID: 33799684
PMC: 7999597.
DOI: 10.3390/ijms22062853.
Monoamine oxidase A activity in fibroblasts as a functional confirmation of variants.
Peters T, Lammerts van Bueren I, Geurtz B, Coene K, de Leeuw N, Brunner H
JIMD Rep. 2021; 58(1):114-121.
PMID: 33728254
PMC: 7932864.
DOI: 10.1002/jmd2.12194.
Design, synthesis, molecular modelling and screening of monoamine oxidase inhibitory activities of novel quinazolyl hydrazine derivatives.
Amer A, Hegazi A, Alshekh M, Ahmed H, Soliman S, Maniquet A
R Soc Open Sci. 2020; 7(4):200050.
PMID: 32431898
PMC: 7211837.
DOI: 10.1098/rsos.200050.
The discovery and development of rasagiline as a new anti-Parkinson medication.
Finberg J
J Neural Transm (Vienna). 2020; 127(2):125-130.
PMID: 31974721
DOI: 10.1007/s00702-020-02142-w.
Selegiline: a molecule with innovative potential.
Tabi T, Vecsei L, Youdim M, Riederer P, Szoko E
J Neural Transm (Vienna). 2019; 127(5):831-842.
PMID: 31562557
PMC: 7242272.
DOI: 10.1007/s00702-019-02082-0.
Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis.
Yeung A, Georgieva M, Atanasov A, Tzvetkov N
Front Mol Neurosci. 2019; 12:143.
PMID: 31191248
PMC: 6549493.
DOI: 10.3389/fnmol.2019.00143.
Inhibitory Effect of (2R)-1-(1-Benzofuran-2-yl)-N-propylpentan-2-amine on Lung Adenocarcinoma.
Mervai Z, Reszegi A, Miklya I, Knoll J, Schaff Z, Kovalszky I
Pathol Oncol Res. 2019; 26(2):727-734.
PMID: 30734151
PMC: 7242259.
DOI: 10.1007/s12253-019-00603-6.
, a Forgotten Potential Therapy for Parkinson's Disease?.
Djamshidian A, Bernschneider-Reif S, Poewe W, Lees A
Mov Disord Clin Pract. 2019; 3(1):19-26.
PMID: 30713897
PMC: 6353393.
DOI: 10.1002/mdc3.12242.
Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.
Finberg J
J Neural Transm (Vienna). 2018; 126(4):433-448.
PMID: 30386930
DOI: 10.1007/s00702-018-1952-7.
Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.
Youdim M
J Neural Transm (Vienna). 2018; 125(11):1719-1733.
PMID: 30341696
DOI: 10.1007/s00702-018-1942-9.
Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Shih J
J Neural Transm (Vienna). 2018; 125(11):1553-1566.
PMID: 30259128
PMC: 6245662.
DOI: 10.1007/s00702-018-1927-8.
A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths.
Gillman P
J Neural Transm (Vienna). 2018; 125(11):1707-1717.
PMID: 30255284
DOI: 10.1007/s00702-018-1932-y.
